The study is being conducted to evaluate the efficacy, safety, and ORR of HRS-4508 in subjects with locally advanced or metastatic non-small cell lung cancer; Evaluate the pharmacokinetic (PK) characteristics of HRS-4508 and other efficacy endpoints for the treatment of locally advanced or metastatic non-small cell lung cancer.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
120
HRS-4508 tablet
Shanghai Pulmonary Hospital
Shanghai, Shanghai Municipality, China
RECRUITINGThe incidence and severity of adverse events (AE)/serious adverse events (SAE) (rated based on CTCAE v5.0)
Time frame: 2 years
Objective response rate (ORR)
Time frame: 1 year
Blood concentrations of HRS-4508
Time frame: 12 weeks
Duration of response (DoR)
Time frame: 1 year
Disease control rate (DCR)
Time frame: 1 year
Progression free survival (PFS)
Time frame: 1 year
Overall survival (OS)
Time frame: 2 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.